ERBB2 and non-small cell lung carcinoma: In the phase I/II SOHO-01 trial, patients with advanced NSCLC harboring a HER2-activating mutation who experienced disease progression after at least one systemic therapy but were naïve to HER2-targeted therapy were enrolled and received BAY 2927088 at 20 mg twice daily.